Skip to main content

Fiscal Wizard · Single-issue tearsheet

PROK / Jun 22, 2026 Run #7706

PROK

ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Composite verdict

F 9.4 / 100
Bearish setup · Reversal 11 drivers · 6 gates blocking
  • Accumulation/Distribution Line
  • Double 7s
  • MA Rejection
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 447th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 14Mean-reversion Bearish 38

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

18.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Assets 77
Free Cash Flow Yield 0
Gross Margin 75
FCF Margin 0
EBITDA Margin 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Accumulation/Distribution Line, Double 7s, MA Rejection); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 10
MA Rejection 14
Double 7s 14

Risk Gates

6 blocking 4 caution

6 guards active, 21 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PROK.